Floatz logo

Tetradecanoylphorbol

Myelodysplastic/Myeloproliferative Diseases

University of Medicine and Dentistry of New JerseyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

46 Active assets in the Myelodysplastic/Myeloproliferative Diseases cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BBB
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
Evomela
M.D. Anderson Cancer Center
Phase 2/3BBB
Busulphan
Jacqueline Garcia, MD
Phase 2/3BBB
Cytosin-Arabinosid
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Tetradecanoylphorbol is also rated in:

plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →
precancerous conditionDormant
CC
Indicative ·
43 / 100
View asset →
myeloproliferative neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →